AstraZeneca is significantly expanding the company’s footprint in China with the establishment of a global R&D center and launch of a $1 billion fund aimed at supporting that nation’s healthcare sector.
Thousand Oaks, California-based Amgen significantly expanded the company’s presence in China by taking a 20.5 percent stake in BeiGene Co.
Oooooh, That’s Scary! Welcome to the Dark Side of Biopharma
Bankruptcy, Biotech, Bioterrorism, Births, Business, Carcinogens, China, CRISPR, Fraud, Gene Editing, Genes, Government, HIV, Medicare, N-nitrosodimethylamine (NDMA), Opioids, Pharma, PhRMA, Restructuring, Spinal Muscular Atrophy (SMA), StudiesFor Halloween, BioSpace collected six tales of thrills and chills from the pharma and biotech industries that will surely have you covering your eyes in terror.
Merck & Co. Inc. expects the company’ immunotherapy Keytruda will continue the drug’s market dominance as an initial treatment for advanced lung cancer as sales of the medicine topped $3 billion in a quarter for the first time, beating lofty Wall Street estimates.
Roche lifted the Swiss drugmaker’s 2019 sales target for the third time during the year, helped by newer medicines and as China bought more cancer drugs to treat a disease blamed for a quarter of the nation’s annual deaths.
A San Diego couple, formerly of Ohio, was charged by the federal government with stealing intellectual property related to pediatric medical treatments from Nationwide Children’s Hospital in order to launch a pharmaceutical company in China.
Collaborating researchers at the University of Iowa and Capital Medical University in China found that a drug used to treat enlarged prostate, terazosin, appears able to slow the progress of Parkinson’s disease.
Sanofi Reports Strong Second-Quarter 2019
Acquisitions, Analysts, Asthma, Atopic Dermatitis (Eczema), Business, China, Chronic Rhinosinusitis, Diabetes, Earnings per share (EPS), European Medicines Agency, FDA, Future Blockbusters, Hemophilia, Insulin, Product Launches, Profitability, Quarterly results, R&D, Relapse/Refractory Multiple Myeloma, VaccinesSanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
AstraZeneca Plc raised the company’s product sales forecast for 2019 after second-quarter results beat analysts’ expectations, thanks to strong sales from cancer medicines and emerging markets, especially China.
New rules went into effect during 2018 on the Hong Kong stock exchange allowing companies that did not have a product on the market or generate revenue to list on the exchange.